CIRRA+ : revenue, balance sheet and financial ratios

CIRRA+ is a French company founded 27 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in FONTANIL-CORNILLON (38120), this company of category PME shows in 2023 a revenue of 1.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - CIRRA+ (SIREN 422747139)
Indicator 2024 2023 2022 2021 2020 2019 2018 2018 2017
Revenue N/C 1 858 227 € 1 722 431 € 1 463 573 € N/C 1 737 472 € N/C 1 428 009 € 1 537 838 €
Net income 122 076 € 14 157 € 51 025 € 31 300 € -9 834 € -57 620 € -54 031 € -65 456 € 36 192 €
EBITDA N/C -71 785 € -64 047 € -75 040 € N/C -19 139 € N/C -97 773 € -8 124 €
Net margin N/C 0.8% 3.0% 2.1% N/C -3.3% N/C -4.6% 2.4%

Revenue and income statement

In 2024, CIRRA+ generates positive net income of 122 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 36 k€ -> 122 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

122 076 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 14%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 48%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

13.848%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

47.971%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

35.0%

Solvency indicators evolution
CIRRA+

Sector positioning

Debt ratio
13.85 2024
2022
2023
2024
Q1: 0.0
Med: 4.27
Q3: 43.96
Average -19 pts over 3 years

In 2024, the debt ratio of CIRRA+ (13.85) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
47.97% 2024
2022
2023
2024
Q1: 14.64%
Med: 38.36%
Q3: 60.56%
Good +12 pts over 3 years

In 2024, the financial autonomy of CIRRA+ (48.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
-9.09 years 2023
2022
2023
Q1: 0.0 years
Med: 0.0 years
Q3: 1.46 years
Excellent

In 2023, the repayment capacity of CIRRA+ (-9.09) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 193.17. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

193.169

Liquidity indicators evolution
CIRRA+

Sector positioning

Liquidity ratio
193.17 2024
2022
2023
2024
Q1: 132.74
Med: 202.27
Q3: 325.9
Average

In 2024, the liquidity ratio of CIRRA+ (193.17) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
-1.88x 2023
2022
2023
Q1: 0.0x
Med: 0.29x
Q3: 6.06x
Average

In 2023, the interest coverage of CIRRA+ (-1.9x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
CIRRA+

Positioning of CIRRA+ in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of CIRRA+ is estimated at 100 287 € (range 38 170€ - 366 236€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
124 transactions
38k€ 100k€ 366k€
100 287 € Range: 38 170€ - 366 236€
NAF 5 all-time

Valuation method used

Net Income Multiple
122 076 € × 0.8x = 100 287 €
Range: 38 170€ - 366 237€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare CIRRA+ with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about CIRRA+

What is the revenue of CIRRA+ ?

The revenue of CIRRA+ in 2023 is 1.9 M€.

Is CIRRA+ profitable?

Yes, CIRRA+ generated a net profit of 122 k€ in 2024.

Where is the headquarters of CIRRA+ ?

The headquarters of CIRRA+ is located in FONTANIL-CORNILLON (38120), in the department Isere.

Where to find the tax return of CIRRA+ ?

The tax return of CIRRA+ is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does CIRRA+ operate?

CIRRA+ operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.